A股異動丨漢鼎宇佑(300300.SZ)漲停 控股股東累計增持120萬股
格隆匯9月18日丨漢鼎宇佑(300300.SZ)漲停,報9.08元,總市值61億元。漢鼎宇佑昨日盤後公佈,截至2020年9月17日,此次增持計劃時間已過半。公司控股股東平潭創投通過深圳證券交易所集中競價交易系統累計增持公司股份120萬股,佔公司總股本的比例為0.1787%。此次增持後,公司控股股東平潭創投持有公司股份1.03億股,佔公司總股本的比例為15.3697%。此前,上交所科創板披露了京東數科招股説明書,漢鼎宇佑全資子公司漢鼎宇佑資本以1090萬元參與發起設立了宿遷漢鼎錦繡投資管理合夥企業,宿遷漢鼎錦繡持有京東數科0.6%股份。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.